EN 
FR 
Advancing Patient Value and Market Access
Cytel provides comprehensive support to help you overcome market access challenges. Our strategic and integrated approach empowers you to navigate the complex regulatory and payer landscapes effectively, ensuring optimal pricing, reimbursement, and patient access.
Leading Market Access Solutions
Navigating market access is paramount for the commercial success of new therapies, from payer negotiations to health-economic evidence. Our tailored strategies align early and throughout the product lifecycle with regulatory, payer, and patient needs. We help you achieve seamless market entry by optimizing evidence generation, stakeholder engagement, and strategic pricing, ultimately enhancing your product value and patient outcomes.
Contact usIntegrated evidence planning
We integrate comprehensive clinical and payer-focused evidence planning to align with your market access requirements, ensuring broader product adoption and reimbursement.
Localized expertise and global insights
Take advantage of Cytel’s local and global market insights to customize your market access strategies, ensure compliance and maximize product reach.
Advanced analytical frameworks
Employ our state-of-the-art analytical tools for strategic forecasting and decision-making, to enhance your market penetration and increase success.
Strategic stakeholder engagement
We facilitate critical engagements with regulators, payers, and healthcare professionals to advocate effectively for your product’s market access.
Addressing Market Access Challenges
Poor market access is the leading cause of underwhelming drug launch performance. Challenges include stringent payer evaluations, complex health technology assessments (HTA), and intense competition. These challenges stem from a poor understanding of market dynamics and customer needs, including inaccurate targeting and underestimation in converting customers. Cytel’s approach integrates asset value considerations early, addressing these hurdles through robust evidence generation and strategic stakeholder engagement to prevent value loss and navigate shrinking access windows effectively.
Streamline Your Market Access Process
Our market access process is meticulously designed to optimize your path from regulatory approval to revenue. This process includes:
- Market access roadmap: Navigating regulatory to revenue paths, emphasizing early scientific advice and strategic payer engagement.
- Value evidence analysis: Assessing and aligning your clinical plans with payer needs and potential HTA outcomes.
- Integrated evidence plan & SLR: Leveraging real-world data and non-RCT data to fill evidence gaps and meet payer and HTA expectations.
- Product value proposition: Developing and validating a strong value proposition that resonates with your payers.
- Value communication: Preparing and executing a communication strategy that encompasses global evidence and meets local payer requirements.
Cytel’s Evidence Hub: Supporting Drug Value Optimization
Cytel’s Evidence Hub plays a crucial role in synthesizing and leveraging data across multiple domains to support your market access:
- Medical affairs: Condenses scientific information to crystallize drug value.
- R&D and clinical development: Provides insights on competitive landscapes, and trial designs, and identifies high-efficacy subgroups.
- Market access and pricing: Develops strategies for HTA and pricing.
- HEOR: Builds budget impact and cost-effectiveness models.
- Commercial and epidemiology: Assesses market utilization and post-marketing safety, crucial for long-term market success.
Strategic Market Access Planning
Our experts help you navigate market access successfully by:
- Planning early: Incorporating payer-relevant comparators and endpoints from the start.
- Developing clear product value propositions: Addressing unmet needs and demonstrating tangible patient benefits supported by robust evidence.
- Engaging with payers early: Establishing and maintaining relationships with payer opinion leaders to ensure alignment on product value.
- Integrating evidence generation: Adopting a cross-functional approach to evidence planning, focusing on clinical, economic, and real-world evidence to support market access strategies.
Enhancing our Global Market Access Through Strategic Acquisitions
Cytel has expanded its market access capabilities through acquisitions such as stève consultants and co.faktor. These acquisitions enrich Cytel’s expertise in navigating complex regulatory environments and optimizing market access strategies, particularly in critical markets like Germany and France. Cytel can now offer more localized and effective market access support, from early scientific advice to reimbursement strategy and dossier preparation, tailored to meet the diverse and rigorous standards of global health authorities and payers.
For 15 years, stève consultants has specialized in:
- Price/reimbursement strategy consulting for health products
- Developing and valorizing scientific and medico-economic evidence in line with health authorities’ requirements (HAS and CEPS), possibly with the support of recognized experts
- Writing and submission of reimbursement dossiers (early access, transparency, CNEDiMTS and economic dossiers)
- Customer support throughout the dossier evaluation by health authorities
stève consultants’ asset is their reputed experience with the latest innovations (CAR-T, immunotherapy, gene therapy, targeted therapy) and orphan drugs.
Germany has the highest expenditure on pharmaceuticals, medical devices and digital health applications (DiGA) of any European country. While this makes the German market very attractive for many companies, it also presents many hurdles and complex regulations, which make market access in Germany extremely challenging and difficult to navigate. Find out how co.faktor supports you in optimizing market access for your medicinal products, medical devices and digital health applications.
Webinar Series on EU-JCA
Watch our recent 2-part webinar series covering EU Joint Clinical Assessment (JCA) and Health Technology Assessment (HTA). The webinars cover the upcoming European HTA regulation, impact on the market, and valuable insights.
Watch Webinar Series
>280
Comparative and cost-effective analyses, budget impact models, indirect treatment comparisons
>150
Global value dossiers, objection handlers & payer value propositions
40+
Value communication and local market access experts
Related Insights
Launch Communication: Addressing HCPs Effectively and Ensuring Product Success
Guide to Successful G-BA Consultations: Practical Tips for Market Access Professionals
Unlocking Germany’s Pharmaceutical Market: A Guide to AMNOG and Market Access
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug's probability of success and plot a clearer route to market.